Literature DB >> 15643200

Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination.

Toyonori Tsuzuki1, David J Hernandez, Hakan Aydin, Bruce Trock, Patrick C Walsh, Jonathan I Epstein.   

Abstract

PURPOSE: There are few studies on predictors of extraprostatic extension (EPE) in the region of the neurovascular bundle (NVB). We investigated whether clinical information and prostate biopsy data could predict EPE of clinical localized prostate cancer.
MATERIALS AND METHODS: Through a retrospective analysis of the pathology database we identified 2,660 cases of clinically localized prostate cancer treated with radical retropubic prostatectomy without preoperative adjuvant therapy at The Johns Hopkins Hospital. The study sample involved a total of 3,006 lobes with prostate cancer including 2,070 with organ confined disease, 620 with EPE in the NVB at the posterolateral edge of the prostate and 316 with EPE in a region other than the NVB (EPE elsewhere). Through univariate and multivariate logistic regression analysis we determined whether patient age, year of surgery, serum prostate specific antigen, digital rectal examination, biopsy highest Gleason score, perineural invasion, percent of side specific biopsy cores with cancer, percent of each core involved with cancer and the maximum percent of a core involved with cancer was predictive of EPE in the NVB.
RESULTS: Prostate specific antigen (10 or greater vs less than 10), biopsy Gleason score (7 or greater vs 6 or less), digital rectal examination (abnormal vs normal), percent of side specific cores with tumor (greater than 33.3% vs 33.3% or less) and average percent involvement of each positive core (greater than 20% vs 20% or less) were all found to be statistically significant independent predictors of NVB penetration in multivariate analysis. The generated model stratifies each of these variables into high and low risk. The probability of EPE in the NVB was less than 10% in cases with 1 or fewer of the higher risk variables and was 10% or greater in cases with more than 1 of the higher risk variables.
CONCLUSIONS: The model generated in this study allows for the preoperative identification of patients with 10% or greater probability of EPE in the NVB. Our algorithm will help provide objective parameters that aid in the decision to spare the NVB safely.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15643200     DOI: 10.1097/01.ju.0000151370.82099.1a

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

Review 1.  [Uro-oncology--update 2009].

Authors:  T Otto
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

Review 2.  Standards for prostate biopsy.

Authors:  Marc A Bjurlin; Samir S Taneja
Journal:  Curr Opin Urol       Date:  2014-03       Impact factor: 2.309

3.  Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.

Authors:  Takuya Koie; Koji Mitsuzuka; Takahiro Yoneyama; Shintaro Narita; Sadafumi Kawamura; Yasuhiro Kaiho; Norihiko Tsuchiya; Tatsuo Tochigi; Tomonori Habuchi; Yoichi Arai; Chikara Ohyama; Tohru Yoneyama; Yuki Tobisawa
Journal:  Int J Clin Oncol       Date:  2014-04-29       Impact factor: 3.402

4.  Preoperative nomograms for predicting extracapsular extension in Korean men with localized prostate cancer: a multi-institutional clinicopathologic study.

Authors:  Jae Seung Chung; Han Yong Choi; Hae-Ryoung Song; Seok-Soo Byun; Seong il Seo; Cheryn Song; Jin Seon Cho; Sang Eun Lee; Hanjong Ahn; Eun Sik Lee; Won-Jae Kim; Moon Kee Chung; Tae Young Jung; Ho Song Yu; Young Deuk Choi
Journal:  J Korean Med Sci       Date:  2010-09-17       Impact factor: 2.153

Review 5.  Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing.

Authors:  Marc A Bjurlin; H Ballentine Carter; Paul Schellhammer; Michael S Cookson; Leonard G Gomella; Dean Troyer; Thomas M Wheeler; Steven Schlossberg; David F Penson; Samir S Taneja
Journal:  J Urol       Date:  2013-02-26       Impact factor: 7.450

Review 6.  Considerations for patient selection for focal therapy.

Authors:  John F Ward; Louis L Pisters
Journal:  Ther Adv Urol       Date:  2013-12

7.  Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Authors:  Lisa F Newcomb; Ian M Thompson; Hilary D Boyer; James D Brooks; Peter R Carroll; Matthew R Cooperberg; Atreya Dash; William J Ellis; Ladan Fazli; Ziding Feng; Martin E Gleave; Priya Kunju; Raymond S Lance; Jesse K McKenney; Maxwell V Meng; Marlo M Nicolas; Martin G Sanda; Jeffry Simko; Alan So; Maria S Tretiakova; Dean A Troyer; Lawrence D True; Funda Vakar-Lopez; Jeff Virgin; Andrew A Wagner; John T Wei; Yingye Zheng; Peter S Nelson; Daniel W Lin
Journal:  J Urol       Date:  2015-08-29       Impact factor: 7.450

8.  Does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes?

Authors:  Stacy Loeb; Jonathan I Epstein; Elizabeth B Humphreys; Patrick C Walsh
Journal:  BJU Int       Date:  2009-08-19       Impact factor: 5.588

Review 9.  Radical prostatectomy for high-risk prostate cancer.

Authors:  Ofer Yossepowitch; James A Eastham
Journal:  World J Urol       Date:  2008-03-12       Impact factor: 4.226

10.  Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.

Authors:  Daniel W Lin; Lisa F Newcomb; Elissa C Brown; James D Brooks; Peter R Carroll; Ziding Feng; Martin E Gleave; Raymond S Lance; Martin G Sanda; Ian M Thompson; John T Wei; Peter S Nelson
Journal:  Clin Cancer Res       Date:  2013-03-20       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.